Amplia Therapeutics Ltd Annual Shareholders Meeting Transcript
Thank you for watching this presentation. My name is John Lambert, and I'm the CEO of Amplia Therapeutics. This presentation was one that I gave at the company's annual general meeting held in Melbourne on August 25, 2022. If you please bear with me for a second while I share my screen, I shall take you through the presentation again.
Please also note the company's disclosure statement shown on this slide. What I'd like to do during this presentation is take you through a bit of an overview of Amplia Therapeutics and our year in review. For those of you who are less familiar with our technology, I'd like to just spend a few minutes talking about that.
But most of this presentation is devoted to describing the ACCENT clinical trial which is a Phase 1b/2a clinical trial recently initiated by the company in patients with first line -- first line patients with pancreatic cancer. At the end of the presentation, I'll touch on our plans for the coming financial year.
I think it's important at the start of a presentation like this, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
